David Arons is the Chief Executive Officer of the National Brain Tumor Society. He previously served in leadership and external positions at the American Cancer Society in Minnesota, the Center for Lobbying in the Public Interest and at Independent Sector. As an attorney, he previously represented patients facing disabilities and serious health conditions. He is the author of several books, including Power in Policy: A Funder’s Guide to Advocacy and Civic Participation, Strengthening Nonprofit Advocacy, and A Voice for Nonprofits. He serves on the National Cancer Institute’s Council of Research Advocates and Clinical Trials Advisory Committee. In 2016, Mr. Arons was named to the Blue Ribbon Panel of experts selected to help advise the National Cancer Moonshot, led by former Vice President Joseph Biden.
Lauren Hall, CFRE
Chief Development Officer
Lauren Hall is the Chief Development Officer at the National Brain Tumor Society. A senior development professional with nearly two decades of experience at some of the world’s leading institutions – including Dana-Farber Cancer Institute, the University of Pennsylvania, and Brigham and Women’s Hospital – Lauren has served as a frontline fundraiser for three multibillion-dollar campaigns. She has secured transformative funding from individuals, corporations, and foundations, built and managed boards and committees, and led highly successful fundraising teams. She previously served as Assistant Vice President of Development at Brigham and Women’s Hospital, where she directed fundraising for the neurosciences and played a key role in launching the Ann Romney Center for Neurologic Diseases.
Kirk Tanner, Ph.D
Chief Scientific Officer
Kirk Tanner is the Chief Scientific Officer at the National Brain Tumor Society. Kirk is an oncology research leader with two decades experience in discovery and development projects and programs resulting in multiple clinical candidate therapies and investigational new drugs. Formerly, he was the Research Oncology Disease Area Expert and Senior Director at Vertex Pharmaceuticals. As CSO, Kirk leads National Brain Tumor Society’s research program that aims to catalyze treatment development through philanthropic investment in medical research, engaging scientists, clinicians, patients and care partners in research programs. Kirk received his Ph.D. in chemistry from the University of California, San Diego and did post-doctoral training at Oregon Health Sciences University.
Chief Financial Officer
Steve Gallucci is the Chief Financial Officer of the National Brain Tumor Society. Steve brings to NBTS over twenty years of experience in financial leadership. He has served non-profits in human services, healthcare, and education, and for-profit organizations in biotech, professional services, and media. He has led organizations from startup to dramatic growth to acquisitions. Most recently, Steve served as a consulting CFO, providing expert council to senior leaders and Boards of Directors. Steve is a licensed CPA and received his MBA from Cornell University.
Sarah Durham is the Chair of the National Brain Tumor Society Board of Directors. She is the CEO of Big Duck, a communications firm that works exclusively with nonprofits experiencing significant growth and change. She was named a top fundraiser under 40 by Fundraising Success in 2006, and one of the most influential women in technology by Fast Company in 2010.
Thomas Roloff – Vice Chair
Thomas Roloff is the vice chairperson of the National Brain Tumor Society. He is senior vice president of Information Technology & Business Transformation at Dell Technologies Corporation. He also attended the MIT Sloan School of Management where he earned an M.B.A. Mr. Roloff was also a vice president of EMC and chief operating officer at EMC Consulting. He has also held senior management positions at Perot Systems and HomeLife Medical. He earned his undergrad degree at Lafayette University and a masters degree at Virginia Tech University.
John Frishkopf – Treasurer
John Frishkopf is the Treasurer of the National Brain Tumor Society Board of Directors and the Chair of the Programs Committee. He is a founder of NewStar Financial, Inc. from which he recently retired as Treasurer and Head of Asset Management. Mr. Frishkopf joined the board of NBTS after his husband, now deceased, was diagnosed with glioblastoma. A graduate of MIT and MIT Sloan, John Frishkopf has spoken at conferences and has published on using financial engineering techniques to speed the drug discovery process.
Robert Burger – Clerk
Robert Burger is the Clerk of the National Brain Tumor Society Board of Directors. He is also the Executive Director and Chief Operating Officer at the global intellectual property law firm of Sterne Kessler Goldstein & Fox headquartered in Washington, D.C. Rob is actively involved in other boards and earned his Bachelor of Arts from Miami University of Ohio, his Master’s degree from American University, and an MBA from Georgetown University. Rob’s aunt founded BTS, an NBTS legacy organization, after tragically losing her son Seth Harris Feldman to a Glioblastoma in December of 1988 (days before his 18th birthday).
Evanthia Galanis, MD
Chandri Navarro, Esq.
Dr. Edjah Nduom
Eric Olson, PhD
Stephen T. Sadler, JD
Salo Zelermyer, JD
Co-Founder: G. Bonnie Feldman The Brain Tumor Society
Co-Founder: Walter & Ellen Newman and David & Nora Plan National Brain Tumor Foundation